PMC:7161517 / 30839-31049 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T164","span":{"begin":107,"end":125},"obj":"Disease"},{"id":"T165","span":{"begin":116,"end":125},"obj":"Disease"}],"attributes":[{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The question remains whether the use of ACE inhibitors, ARBs, and MRAs should be avoided in the setting of SARS-CoV infection because each agent (42, 43, 44, 45, 46,53) upregulates ACE2 expression and activity."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T292","span":{"begin":158,"end":160},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T293","span":{"begin":201,"end":209},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"The question remains whether the use of ACE inhibitors, ARBs, and MRAs should be avoided in the setting of SARS-CoV infection because each agent (42, 43, 44, 45, 46,53) upregulates ACE2 expression and activity."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T324","span":{"begin":40,"end":54},"obj":"Chemical"},{"id":"T325","span":{"begin":44,"end":54},"obj":"Chemical"}],"attributes":[{"id":"A324","pred":"chebi_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"The question remains whether the use of ACE inhibitors, ARBs, and MRAs should be avoided in the setting of SARS-CoV infection because each agent (42, 43, 44, 45, 46,53) upregulates ACE2 expression and activity."}

{"project":"LitCovid-sentences","denotations":[{"id":"T188","span":{"begin":0,"end":210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The question remains whether the use of ACE inhibitors, ARBs, and MRAs should be avoided in the setting of SARS-CoV infection because each agent (42, 43, 44, 45, 46,53) upregulates ACE2 expression and activity."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1008","span":{"begin":44,"end":54},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T1009","span":{"begin":107,"end":115},"obj":"SP_10"},{"id":"T1010","span":{"begin":181,"end":185},"obj":"G_3;PG_10;PR:000003622"},{"id":"T1011","span":{"begin":186,"end":196},"obj":"GO:0010467"},{"id":"T77253","span":{"begin":44,"end":54},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T68013","span":{"begin":107,"end":115},"obj":"SP_10"},{"id":"T90735","span":{"begin":181,"end":185},"obj":"G_3;PG_10;PR:000003622"},{"id":"T99855","span":{"begin":186,"end":196},"obj":"GO:0010467"}],"text":"The question remains whether the use of ACE inhibitors, ARBs, and MRAs should be avoided in the setting of SARS-CoV infection because each agent (42, 43, 44, 45, 46,53) upregulates ACE2 expression and activity."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1296","span":{"begin":40,"end":43},"obj":"Gene"},{"id":"1297","span":{"begin":181,"end":185},"obj":"Gene"},{"id":"1299","span":{"begin":107,"end":125},"obj":"Disease"}],"attributes":[{"id":"A1296","pred":"tao:has_database_id","subj":"1296","obj":"Gene:1636"},{"id":"A1297","pred":"tao:has_database_id","subj":"1297","obj":"Gene:59272"},{"id":"A1299","pred":"tao:has_database_id","subj":"1299","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The question remains whether the use of ACE inhibitors, ARBs, and MRAs should be avoided in the setting of SARS-CoV infection because each agent (42, 43, 44, 45, 46,53) upregulates ACE2 expression and activity."}

{"project":"2_test","denotations":[{"id":"32305401-16179584-55252999","span":{"begin":146,"end":148},"obj":"16179584"},{"id":"32305401-15159288-55253000","span":{"begin":150,"end":152},"obj":"15159288"},{"id":"32305401-15833808-55253001","span":{"begin":154,"end":156},"obj":"15833808"},{"id":"32305401-27085217-55253002","span":{"begin":158,"end":160},"obj":"27085217"},{"id":"32305401-15007027-55253003","span":{"begin":162,"end":164},"obj":"15007027"},{"id":"32305401-9461243-55253004","span":{"begin":165,"end":167},"obj":"9461243"}],"text":"The question remains whether the use of ACE inhibitors, ARBs, and MRAs should be avoided in the setting of SARS-CoV infection because each agent (42, 43, 44, 45, 46,53) upregulates ACE2 expression and activity."}